Literature DB >> 15322492

Telomerase in breast cancer: a critical evaluation.

Atac Baykal1, Daniel Rosen, Chenyi Zhou, Jinsong Liu, Aysegul A Sahin.   

Abstract

Human chromosomes have highly specialized structures at their ends termed telomeres, repetitive, non-coding DNA sequences (5'-TTAGGG-3'), ranging in size from 5 to 20 kb in human cells. These highly specialized structures prevent chromosome ends from being recognized as double-strand DNA breaks, and they also provide protection from destabilizing agents. The mechanism for maintaining telomere integrity is controlled by telomerase, a ribonucleoprotein enzyme that specifically restores telomere sequences lost during replication by using an intrinsic RNA component as a template for polymerization. Telomerase has two core functional components required for its activity: the catalytic subunit of human telomerase reverse transcriptase (hTERT) and a telomerase RNA template (hTR). Telomerase is activated in the majority of immortal cell lines in culture and in most malignant tumors. This review outlines our current understanding of telomerase in breast cancer development and critically evaluates potential utilities in diagnosis, prognosis, and therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15322492     DOI: 10.1097/01.pap.0000138145.19258.64

Source DB:  PubMed          Journal:  Adv Anat Pathol        ISSN: 1072-4109            Impact factor:   3.875


  8 in total

1.  Elevated TRF2 in advanced breast cancers with short telomeres.

Authors:  Malissa C Diehl; Michael O Idowu; Katherine N Kimmelshue; Timothy P York; Colleen K Jackson-Cook; Kristi C Turner; Shawn E Holt; Lynne W Elmore
Journal:  Breast Cancer Res Treat       Date:  2010-07-13       Impact factor: 4.872

2.  Biology of SNU cell lines.

Authors:  Ja-Lok Ku; Jae-Gahb Park
Journal:  Cancer Res Treat       Date:  2005-02-28       Impact factor: 4.679

3.  Telomerase activity in breast cancer patients: association with poor prognosis and more aggressive phenotype.

Authors:  Ana Kulić; Natalija Dedić Plavetić; Stjepan Gamulin; Jasminka Jakić-Razumović; Damir Vrbanec; Maja Sirotković-Skerlev
Journal:  Med Oncol       Date:  2016-01-30       Impact factor: 3.064

4.  Antiproliferative effects of cucurbitacin B in breast cancer cells: down-regulation of the c-Myc/hTERT/telomerase pathway and obstruction of the cell cycle.

Authors:  Suwit Duangmano; Sumana Dakeng; Weena Jiratchariyakul; Apichart Suksamrarn; Duncan R Smith; Pimpicha Patmasiriwat
Journal:  Int J Mol Sci       Date:  2010-12-22       Impact factor: 5.923

5.  Telomerase activity, estrogen receptors (alpha, beta), Bcl-2 expression in human breast cancer and treatment response.

Authors:  Blanca Murillo-Ortiz; Horacio Astudillo-De la Vega; Sebastian Castillo-Medina; J M Malacara; Luis Benitez-Bribiesca
Journal:  BMC Cancer       Date:  2006-08-15       Impact factor: 4.430

6.  Reduced hTERT protein levels are associated with DNA aneuploidy in the colonic mucosa of patients suffering from longstanding ulcerative colitis.

Authors:  Mariann Friis-Ottessen; Paula M De Angelis; Aasa R Schjølberg; Solveig N Andersen; Ole Petter F Clausen
Journal:  Int J Mol Med       Date:  2014-03-20       Impact factor: 4.101

7.  Estrogen induction of telomerase activity through regulation of the mitogen-activated protein kinase (MAPK) dependent pathway in human endometrial cancer cells.

Authors:  Chunxiao Zhou; Tara A Steplowski; Hallum K Dickens; Kimberly M Malloy; Paola A Gehrig; John F Boggess; Victoria L Bae-Jump
Journal:  PLoS One       Date:  2013-02-07       Impact factor: 3.240

8.  Genetic variation in five genes important in telomere biology and risk for breast cancer.

Authors:  S A Savage; S J Chanock; J Lissowska; L A Brinton; D Richesson; B Peplonska; A Bardin-Mikolajczak; W Zatonski; N Szeszenia-Dabrowska; M Garcia-Closas
Journal:  Br J Cancer       Date:  2007-08-14       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.